NEW HAVEN, CT – January 30, 2024: Leading neuroscience technology company, Cogstate Ltd (ASX.CGS), announced today that Pamela Ventola, PhD has been appointed as the company’s Chief Science Officer (CSO). In this role, Pam will oversee the company’s global science organization in driving innovation, providing strategic guidance and support to customers, and contributing to the company’s continued growth in Clinical Trials and Healthcare. Chris Edgar, PhD, Cogstate’s previous CSO, will be transitioning to the role of Executive Scientific Advisor at Cogstate.
“Pam is an exceptional scientist, leader and trusted adviser to the customer teams with whom she works,” said Brad O’Connor, Cogstate CEO. “Pam brings with her extensive experience across all stages of clinical trial planning and execution; she has a proven track record of delivering innovative solutions that reduce burden for patients and sites and yield high quality data for sponsor teams. I’m also incredibly grateful for the many contributions Chris Edgar has made as CSO and will continue to make as Executive Scientific Advisor. We are pleased for the opportunity for our colleagues and customers to continue to engage his deep expertise in Alzheimer’s disease, cognitive assessment, and clinical endpoint strategy.
Pam joined Cogstate in 2016 and has served as VP of Science and the Director of the Pediatric and Rare Disease portfolio. In addition to her work at Cogstate, Pam is an Associate Professor at the Yale Child Study Center and a licensed clinical psychologist with expertise in pediatric neuropsychology and developmental and genetic disorders.
“It is truly an honor to lead the remarkable team of scientists and operational experts at such a forward-thinking organization and during such a pivotal time of increasing CNS research investment,” said Pam. “I look forward to working hand-in-hand with my colleagues and our clients to deliver innovative approaches to study delivery for patients, families, and communities battling challenging diseases and disorders.”
Pam received her Doctor of Philosophy in Clinical Psychology from the University of Connecticut and completed her clinical training and Postdoctoral Fellowship at the Yale University School of Medicine, Child Study Center. She serves on the editorial review board of multiple academic journals and has authored more than 150 peer-reviewed manuscripts, book chapters, and scientific presentations.
“I have benefitted hugely from my six years with Cogstate and look forward to continuing to play a role in the growth of the organization in this new capacity,” said Chris Edgar. “As a business and as a team of people, Cogstate are uniquely positioned to support drug development, healthcare, and wider clinical research in ways that have the potential to make a real difference to patients and families, as well as healthcare systems and wider society.
###
